Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB)
Daniel Cowley, Rini Mulia Sari, Amanda Handley, Emma Watts, Novilia S Bachtiar, Jarir At Thobari, Cahya Dewi Satria, Nada Bogdanovic-Sakran, Hera Nirwati, Francesca Orsini, Katherine J Lee, Carl D Kirkwood, Yati Soenarto, Julie E Bines
Vaccine | ELSEVIER SCI LTD | Published : 2019
BACKGROUND: The RV3-BB human neonatal rotavirus vaccine was developed to provide protection from severe rotavirus disease from birth. The aim of this study was to investigate the potential for mutual interference in the immunogenicity of oral polio vaccine (OPV) and RV3-BB. METHODS: A randomized, placebo-controlled trial involving 1649 participants was conducted from January 2013 to July 2016 in Central Java and Yogyakarta, Indonesia. Participants received three doses of oral RV3-BB, with the first dose given at 0-5 days (neonatal schedule) or ~8 weeks (infant schedule), or placebo. Two sub-studies assessed the immunogenicity of RV3-BB when co-administered with either trivalent OPV (OPV grou..View full abstract
Awarded by NHMRC CDA fellowship
This trial was funded by the Australian National Health and Medical Research Council, the Bill and Melinda Gates Foundation, PT Bio Farma. C.D.K was supported by an NHMRC CDA fellowship (607347). This research at Murdoch Children's Research Institute was supported by the Victorian Government's Operational Infrastructure Support Program. The Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada received funds as part of a clinical trial agreement with Murdoch Children's Research Institute and PT Bio Farma.